推薦產品
等級
pharmaceutical primary standard
API 家族
mesalazine, mesalamine
製造商／商標名
EDQM
mp
275-280 °C (dec.) (lit.)
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
Nc1ccc(O)c(c1)C(O)=O
InChI
1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
InChI 密鑰
KBOPZPXVLCULAV-UHFFFAOYSA-N
基因資訊
human ... ALOX5(240) , PPARG(5468) , PTGS1(5742) , PTGS2(5743)
尋找類似的產品？ 前往 產品比較指南
相關產品
產品號碼
描述
訂價
訊號詞
Warning
危險分類
Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 2
閃點（°F）
No data available
閃點（°C）
No data available
客戶也查看了
Jeffrey B Raskin et al.
Gastroenterology, 147(4), 793-802 (2014-07-20)
No therapy has been proven to prevent the recurrence of diverticulitis. Mesalamine has shown efficacy in preventing relapse in inflammatory bowel disease, and there is preliminary evidence that it might be effective for diverticular disease. We investigated the efficacy of
David T Rubin et al.
Inflammatory bowel diseases, 14(2), 265-274 (2007-10-13)
A roundtable consensus meeting was held to consolidate current knowledge on the etiology of colorectal cancer in patients with inflammatory bowel disease and to review current strategies, both diagnostic and preventive, specifically addressing the role of 5-aminosalicylic acid. Specific topics
Max Karner et al.
The American journal of gastroenterology, 109(7), 1041-1051 (2014-05-07)
Phosphatidylcholine is a key component of the mucosal barrier. Treatment with modified release phosphatidylcholine aims to improve the impaired barrier function. The primary objective is to evaluate the efficacy of LT-02, a newly designed modified release phosphatidylcholine formula, in a
A M Schoepfer et al.
Alimentary pharmacology & therapeutics, 40(8), 930-937 (2014-08-26)
There is uncertain evidence of effectiveness of 5-aminosalicylates (5-ASA) to induce and maintain response and remission of active Crohn's disease (CD), and weak evidence to support their use in post-operative CD. To assess the frequency and determinants of 5-ASA use
A H Steinhart et al.
Alimentary pharmacology & therapeutics, 25(12), 1389-1399 (2007-06-02)
To evaluate the effectiveness of pH 6-/pH 7-dependent and controlled-release mesalazines in maintaining medically and surgically induced Crohn's disease remission. A systematic search identified 13 randomized controlled trials (RCTs). The rate of symptomatic relapse (Crohn's disease activity index >150, or
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務